The global sales of HIV diagnostics is estimated to be worth USD 3,497.2 million in 2024 and anticipated to reach a value of USD 7,207.7 million by 2034. Sales are projected to rise at a CAGR of 7.5% over the forecast period between 2024 and 2034. The revenue generated by HIV diagnostics in 2023 was USD 3,253.2 million.
The market for HIV diagnostics includes the range of instruments, tests, and assays used to identify if a person has the human immunodeficiency virus (HIV). Because managing and controlling the spread of HIV requires early and reliable diagnosis of the virus, this market is essential to the global healthcare scene.
Diagnostic tools for HIV are available in a large variety from quick tests to lab-based complex tests. These include rapid tests, western blot tests, ELISA and nucleic acid based tests. These tests are used for both screening as well as monitoring viral load and effectiveness of therapy in patients undergoing treatment.
Global HIV Diagnostics Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 3,253.2 million |
| Estimated Size, 2024 | USD 3,497.2 million |
| Projected Size, 2034 | USD 7,207.7 million |
| Value-based CAGR (2024 to 2034) | 7.5% |
The HIV diagnostics industry is set to experience upward growth during the forecast period. It is projected to rise 1.7 times the current market value through 2034.
The HIV/AIDS market characterized by its role in public health, the technical progress to date, and continuing international efforts against the virus. As new diagnostic techniques come with more effective drugs, the potential exists for further market development in early detection and individualized treatment to enhance the quality of life of those living with HIV.
HIV/AIDS market is one public health critical sector as it has to deal with management and fighting one of the biggest health problems globally. The component to early diagnosis and personalized patient management is the continued technical development in this area, which is in line with ongoing international initiatives.
One of the mover factors in the development of the market is the progress in the field of diagnostic techniques. New technologies allow identification of HIV at earlier stages of infection, which is important for good management and effective treatment. Its early diagnosis gives an opportunity for timely intervention, and the progression and transmission of the virus are reduced.
This has been supported by point-of-care testing involving rapid results, greatly improving accessibility to HIV tests, especially in resource-limited settings. Advancements made do not only increase the rate of early detection, increasing capacity for immediate linkages to care, but also improve outcomes.
Moreover, it is also updated with more powerful drugs which have higher efficacy with reduced side effects. The newer molecules in antiretroviral therapy have brought considerable change by being more convenient in dosing regimens and better tolerability.
The development of long-acting injectable ART and novel drug delivery systems is a major step forward in terms of flexibility and adherence to treatment in patients. These developments will be very important in enhancing the quality of life for people living with HIV, reducing burdens from the daily intake of medicines, and promoting better health outcomes.
The table below offers a comparative analysis of the Compound Annual Growth Rate (CAGR) fluctuations for the global HIV diagnostics market between the base year (2023) and the current year (2024) over a six-month period.
This examination uncovers significant changes in market performance and highlights trends in revenue generation, giving stakeholders valuable insights into the market’s growth trajectory throughout the year. The first half (H1) encompasses January through June, while the second half (H2) covers July through December.
In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 8.0%, followed by a slightly higher growth rate of 7.8% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 8.0% (2023 to 2033) |
| H2 | 7.8% (2023 to 2033) |
| H1 | 7.5% (2024 to 2034) |
| H2 | 7.1% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 7.5% in the first half and remain relatively moderate at 7.1% in the second half. In the first half (H1) the market witnessed a decrease of 50 BPS while in the second half (H2), the market witnessed a decrease of 70 BPS.
Growing Prevalence of HIV/Aids to Drive the Market
Most infected HIV patients are between the age group of 15 to 49 and the prevalence rate has been stable since 2001. The overall number of HIV positive patients has increased despite the stabilization.
A rise from 31.5 million in 2010 to 39 million individuals in 2022 is recorded. This rise attributes to the longevity of new infections and increased life expectancy of infected population. Among the 39 million infected 1.5 million were minors and rest adults.
HIV detection over the years has been greatly improved primarily attributed by the expanded capacity of HIV testing capabilities. Yet nearly 14% of HIV-positive patients, are unaware of their status. This gap highlights the critical need for more widely available and easily accessible diagnostic tools to find instances that go untreated, support early intervention, and stop the virus's spread.
The market for HIV diagnostics is expected to develop in light of these factors. The need for cutting-edge diagnostic technology is driven by the ongoing increase in the number of HIV positive individuals as well as the significant percentage of cases that remain undetected.
Raising awareness and promoting testing are crucial for controlling the epidemic as well as managing individual health outcomes and public health activities. In order to meet these objectives, guarantee prompt diagnosis, and enable efficient treatment plans, it is imperative that cutting-edge diagnostic technologies be continuously developed and implemented.
Growing Demand and Market Expansion for HIV Diagnostics
The increasing demand for HIV diagnostics is highly attributed to identifying key virus strains, which is the causative agent of acquired immunodeficiency syndrome (AIDS). Primary samples of serum, saliva, or urine are used in HIV testing to determine the presence of the virus.
These tests are crucial for detecting HIV-related antibodies, antigens, and RNA, allowing for early diagnosis and efficient treatment of the illness.
Rise in awareness of HIV, increased efforts towards privacy for testing, improved accessibility to tests and counseling services are some of the key factors that contribute to the expansion of this market.
Costing Related to HIV Diagnostics may Restrict HIV Diagnostics Market Growth
The market for HIV diagnostics is being held back significantly by the high expenses of nucleic acid testing (NAT).
Although incredibly precise and able to diagnose HIV at an early stage, NAT requires expensive technology and equipment to acquire and maintain. NAT test requires high cost and quality of consumables and specialized trained staff that contribute to the high cost of this test.
This prevents the medical facilities to adopt and regularly use NAT for HIV diagnosis, particularly those with tight finances. This expensive obstacle prevents NAT from being widely implemented, which in turn prevents this cutting-edge diagnostic technique from being more widely available and accessible.
The HIV diagnostics market is further constrained by the absence of NAT requirements in developing countries, in addition to the high costs. In most middle and low income countries the guidelines and regulations for NATs is not significant this results in healthcare systems to adopt less accurate testing modes due to cost constraints.
Healthcare providers have less incentive to invest in NAT technology when governments and international health organizations do not provide mandates or financial support.
As a result, efforts to control and reduce the transmission of the virus are negatively impacted, since undeveloped countries continue to have greater percentages of HIV cases that go undiagnosed or are discovered later in life.
The global HIV diagnostics industry recorded a CAGR of 5.3% during the historical period between 2019 and 2023. The growth of HIV diagnostics industry was positive as it reached a value of USD 3,253.2 million in 2023 from USD 2,477.7 billion in 2019.
The demand for HIV diagnostics is expected to increase because they offer quick and easy tests with visual results, and home sample collection that can be used by both healthcare workers and individuals at home. These benefits are driving the sales of HIV diagnostic methods and helping the market grow.
The rapid adoption of point-of-care (POC) tools and tests globally will also indirectly drive the sales of HIV diagnostic POC products. Rapid tests are simple and are affordable making them top choice for most patients. Furthermore, use of POC at home tests is becoming more popular due to the choice of privacy and comfort of at-home testing.
With PoC HIV testing, counseling and screening happen at the same time while the patient is still in the lab. If needed, confirmation tests are done on the spot. Since both pre-test and post-test counseling are provided during the visit, patients do not need to return for their results, making it a very convenient option. Because of these factors, the demand for HIV diagnostics is expected to grow significantly in the coming years.
Leaders in the industry with a revenue over USD 100 million, or 72.4% of the worldwide market, are referred to as Tier 1 firms. The top players in the HIV diagnostics industry are renowned for their broad product offers and high manufacturing capacities.
These industry experts have a solid clientele, a wealth of knowledge spanning several geographic areas, and proficiency in producing and renovating a wide range of package styles.
In order to guarantee the highest quality, they provide a wide range of goods, including production, recycling, and refurbishing, all of which adhere to the most recent legal and technological criteria. Abbott Laboratories, Thermo-Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., and Merck & Co. Inc. are significant participants in the upper segment of the market.
Medium-sized companies in the HIV testing market, known as Tier 2 companies, make between USD 50 to USD 100 million in sales. They're significant in certain areas and have about a quarter of the market. These companies are well-known globally and understand the market well.
They have good technology and follow the rules, but they might not have the latest technology or be present everywhere. Some important Tier 2 players include Bristol-Myers Squibb Company, Danaher Corporation, Gilead Sciences, Inc., and Zyomtronix, Inc.
Tier 3 comprises most small businesses with less than USD 50 million in revenue that operate locally and cater to specific markets. These businesses are categorized in the tier 3 share sector because they are particularly focused on meeting the needs of the local market.
Their geographical reach is restricted and they operate on a small basis. In this particular context, Tier 3 is classified as an unorganized market, which refers to an industry that lacks considerable structure and formalization in contrast to its organized rivals.
The section below covers the industry analysis for the HIV diagnostics market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a value share of 82.5% through 2034. In Asia Pacific, South Korea is projected to witness a CAGR of 8.0% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| Canada | 5.5% |
| Argentina | 4.8% |
| France | 5.2% |
| Poland | 4.6% |
| Indonesia | 5.3% |
| South Korea | 8.0% |
| GCC Countries | 3.9% |
Germany’s HIV diagnostics market is poised to exhibit a CAGR of 3.2% between 2024 and 2034. Currently, Germany holds the maximum share in the European Union, and this trend is expected to continue during the forecast period.
Federal Ministry of Health in Germany has taken proactive steps towards combating HIV, focusing on early prevention, testing, and treatment. Central to their strategy are public initiatives that ensure comprehensive health coverage and widespread awareness.
Germany’s healthcare system stands out for its free and confidential HIV testing services, which are available to everyone, including high-risk groups and marginalized communities.
Prominent academic institutions collaborate and works together to provide an excellent environment in which cutting-edge instruments and treatments are continuously being created and enhanced.
In view of this solid collaboration among the academic institutions, business, and medical experts, Germany will firmly be at the top in the area of research on HIV and the medical application that goes with it.
Germany has made huge contributions to fighting the virus at international levels and has improved the quality of life for those living with HIV through innovative research and offering robust healthcare.
The market of HIV diagnostics in the USA is expected to grow at a CAGR of 3.2% from 2024 to 2034. According to the National Library of Medicine, USA has a comparatively high HIV prevalence when compared to other countries.
The USA government spends hundreds of millions of dollars funding research for HIV, almost solely through the NIH, which administers many different research programs. These programs fund a broad portfolio of research cutting across basic studies of the virus, new treatments, and possible cure research.
In 2022, in the United States and 6 territories and freely associated states, there were 38,043 HIV diagnoses, more than half of which (52%) occurred among people living in the South.
The National HIV/AIDS Strategy for the United States (NHAS) sets bold targets for ending HIV in the United States by 2030, including a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030.
Significant funding for HIV testing and treatment is made available by initiatives like the President's Emergency Plan for AIDS Relief (PEPFAR) and the Ryan White HIV/AIDS Programme.
Economic development in China's is quiet rapid and is accompanied by an equivalent strengthening of its diagnostic testing infrastructure by setting up reference laboratories, and thus access to these services such as early diagnosis and further treatment for HIV.
China has worked with a number of international organization such as the World Health Organization and UNAIDS, in particular to improve response to the HIV/AIDS epidemic.
With improved access to healthcare services, the rate of diagnosis and treatment of HIV has increased in China. Rising government attempts to fight the global pandemic through various reformatory measures in healthcare, coupled with growing public awareness of HIV/AIDS, are boosting demand for tests like HIV in China.
Due to the increased awareness, many people are coming forward to get themselves voluntarily tested for HIV, which is very helpful in early diagnosis and improves the treatment outcome.
Public awareness about HIV/AIDS has increased really fast in the past couple of years in China because of aggressive education campaigns and other public health initiatives. Often initiated by the government in conjunction with NGOs and international agencies, such campaigns stressed reducing stigma from HIV/AIDS, and testing regularly, particularly in high-risk groups.
The section contains information about the leading segments in the industry. By product, the consumable segment is estimated to grow at a CAGR of 4.4% throughout 2034.
| Product | Consumable |
|---|---|
| Value Share (2034) | 55.6% |
Consumables hold the largest chunk of the market share in terms of revenue among the product segment, holding a share of 55.6% in 2024. Some of the key factors attributing to the growth of the segment are, frequent testing for diagnosis of high-risk groups and rising awareness and uptake of public health screening programs.
There is growing dependency on consumables for various diagnostic procedures. Examples of consumables include test kits, reagents, and other consumables used in labs for the successful detection of HIV. As the world at large now focuses on the early diagnosis and effective management of HIV, the consumables are likely to be on a higher demand.
Home test kits are becoming more and more popular since they enable patients to test in the comfort of their home and maintains privacy. These tests also have a number of consumable parts such as buffer solutions, test cartridges or strips, and lancets for finger stick blood collection that are usually included in these kits.
The growing need for consumables in this market is partly attributed to the discretion and convenience that home testing kits provide.
| Test type | Antibody Tests |
|---|---|
| Value Share (2034) | 42.5% |
The antibody tests segment is forecast to account for a revenue of over USD 3,063.3 million in the HIV diagnostics market by 2034 end. Antibody tests are frequently used in prenatal screening, general healthcare screenings, and volunteer HIV testing campaigns, among other population screening initiatives.
These programmers’ dominance in the HIV diagnostics industry is partly due to the extensive use of antibody testing in them. Antibody tests cost less than combination and NAT. Their cost-effectiveness allows for wider accessibility and supports extensive screening initiatives.
Antibody tests represent the major share in the HIV Diagnostics Market since they are used in the detection of HIV infection. In the case of quick diagnostic tools, they usually come first into line due to their high accuracy, reliability, and ease of use.
Antibody testing has been widely adopted within clinical as well as home settings, effectively making them the top contributors of any particular segment by market size to the marketing division of the HIV diagnostics market.
Important companies in the HIV testing business are making acquisitions and investments in cutting-edge facilities. In order to expand their footprint and further pierce the HIV diagnostics industry throughout several locations, major HIV diagnostics providers have also begun purchasing smaller competitors.
Recent Industry Developments in HIV Diagnostics Market:
In terms of product, the industry is divided into consumables, instruments, software & services.
In terms of indication, the industry is segregated into antibody tests, viral load tests, CD4 tests and others.
The industry is classified by end user as diagnostic laboratories, hospitals and others.
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East & Africa have been covered in the report.
The global HIV diagnostics industry is projected to witness CAGR of 7.5% between 2024 and 2034.
The global HIV diagnostics industry stood at USD 3,253.2 million in 2023.
The global HIV diagnostics industry is anticipated to reach USD 7,207.7 billion by 2034 end.
USA is set to record the CAGR of 3.2% in the assessment period.
The key players operating in the global HIV diagnostics industry include Siemens Healthineers, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Danaher Corporation, Thermo-Fisher Scientific Inc., Bristol-Myers Squibb Company, Janssen Global Services, LLC, Gilead Sciences, Inc., Merck & Co. Inc., QIAGEN, Apogee Flow Systems, Point Care, Zyomtronix, Inc.
Explore Similar Insights
HIV Diagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
